Literature DB >> 24210101

Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy.

Clemens Thoma1, Veronique Bachy, Patricia Seaton, Nicola K Green, David R Greaves, Linda Klavinskis, Leonard W Seymour, Joanne Morrison.   

Abstract

In a phase II/III clinical trial intraperitoneal (i.p.) administration of a group C adenovirus vector (Ad5) caused bowel adhesion formation, perforation and obstruction. However, we had found that i.p. group B, in contrast to group C adenoviruses, did not cause adhesions in nude BALB/c ovarian cancer models, prompting further investigation. Ex vivo, group B Ad11 caused lower inflammatory responses than Ad5 on BALB/c peritoneal macrophages. In vivo, i.p. Ad11 triggered short-term cytokine and cellular responses equal to Ad5 in both human CD46-positive and -negative mice. In contrast, in a long-term study of repeated i.p. administration, Ad11 caused no/mild, whereas Ad5 induced moderate/severe adhesions and substantial liver toxicity accompanied by elevated levels of IFNγ and VEGF and loss of i.p. macrophages, regardless of CD46 expression. It appears that, although i.p. Ad11 evokes immediate inflammation similar to Ad5, repeated administration of Ad11 is better tolerated and long-term fibrotic tissue remodelling is reduced.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ad11; Ad5; Adenovirus; CD46-transgenic mice; Gene therapy; Intraperitoneal inflammation; Ovarian cancer; Virotherapy

Mesh:

Substances:

Year:  2013        PMID: 24210101     DOI: 10.1016/j.virol.2013.08.032

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Oncolytic adenovirus Ad11 enhances the chemotherapy effect of cisplatin on osteosarcoma cells by inhibiting autophagy.

Authors:  Bin Zhang; Yan Zhang; Rongzhen Li; Jiazhen Li; Xinchang Lu; Yi Zhang
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

Review 2.  Gene Therapy Used in Cancer Treatment.

Authors:  Thomas Wirth; Seppo Ylä-Herttuala
Journal:  Biomedicines       Date:  2014-04-08

3.  OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution.

Authors:  Irene Kuhn; Maxine Bauzon; Nicola Green; Len Seymour; Kerry Fisher; Terry Hermiston
Journal:  Mol Ther Oncolytics       Date:  2016-12-14       Impact factor: 7.200

Review 4.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

5.  Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers.

Authors:  Young-Suk Cho; Manh-Hung Do; Se-Young Kwon; Changjong Moon; Kwonseop Kim; Keesook Lee; Sang-Jin Lee; Silvio Hemmi; Young-Eun Joo; Min Soo Kim; Chaeyong Jung
Journal:  Oncotarget       Date:  2016-06-21

6.  Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.

Authors:  Natalya Belousova; Galina Mikheeva; Chiyi Xiong; Loren J Stagg; Mihai Gagea; Patricia S Fox; Roland L Bassett; John E Ladbury; Michael B Braun; Thilo Stehle; Chun Li; Victor Krasnykh
Journal:  Oncotarget       Date:  2016-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.